BASILDON, UK, 1 June 2023
Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today confirmed the appointment of David Murray as its Chief Financial Officer, effective immediately.
David joined Pharmanovia in June 2023. He has over 35 years’ experience leading finance functions in global organisations.
Before joining Pharmanovia, David was CFO for BVI. Prior to this he was with Novartis for almost 20 years as CFO in the Pharma, Vaccines and Diagnostics and Alcon (eye care) Divisions. David’s extensive experience includes driving top line growth and M&A/Licensing portfolio expansions.
David holds an MA, Economics from Aberdeen University and is a fellow of the Chartered Institute of Management Accountants (FCMA).
Pharmanovia confirmed that Felipe Florez will be stepping down from role, effective May 2023. The team will work on a smooth transition of responsibilities.
Commenting, James Burt, CEO, Pharmanovia: “I’m excited to welcome David, who brings a wealth of expertise to add to the strength of our team. I’d also like to take this opportunity to thank Felipe for the last two years where he oversaw a number of important global projects. With David on board, we are in an excellent position to embark upon the next phase of our growth.”
Felipe Florez added, “I wish to thank the Pharmanovia team and its shareholders for the last two years. During this time the business has undergone a significant transformation, delivering consistent organic growth and expanded leadership in lifecycle management. I wish the company ongoing success and I look forward to a smooth transition and my next opportunity.”
Notes to editors
For further information, please contact:
Alison Dyson, Director of Communications, Pharmanovia
07442 256310/ Alison.firstname.lastname@example.org
Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.
We do this by rediscovering, repurposing or re-engineering established medicines to improve patient outcomes and experiences as well as identifying new chemical entities that complement our existing portfolio to address unmet need.
With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.